No Data
No Data
Needham Reiterates Buy on Cidara Therapeutics, Maintains $25 Price Target
Needham analyst Joseph Stringer reiterates Cidara Therapeutics (NASDAQ:CDTX) with a Buy and maintains $25 price target.
Buy Rating Justified by Cidara Therapeutics' Upcoming Clinical Trials and Expanding Oncology Pipeline
Cidara Therapeutics | 10-Q: Quarterly report
Cidara Therapeutics (CDTX.US): The 2024 Q1 financial report achieved revenue of US$8.463 million, with a previous value of US$25.99 million, with an expected value of US$9.03 million; earnings per share was -2.28 USD, previous value of USD 0.60, and expec
Cidara Therapeutics (CDTX.US): The 2024 Q1 financial report achieved revenue of US$8.463 million, with a previous value of US$25.99 million, with an expected value of US$9.03 million; earnings per share was -2.28 USD, previous value of USD 0.60, and expected value of -0.80 USD.
Cidara Therapeutics: Closed a $240M Private Placement Led by RA Cap Management >CDTX
Cidara Therapeutics: Closed a $240M Private Placement Led by RA Cap Management >CDTX
Cidara Therapeutics Q1 2024 GAAP EPS $(2.28) Misses $(0.20) Estimate, Sales $8.46M Beat $6.30M Estimate
Cidara Therapeutics (NASDAQ:CDTX) reported quarterly losses of $(2.28) per share which missed the analyst consensus estimate of $(0.20) by 1040 percent. The company reported quarterly sales of $8.46